November was basically the month tech stocks decided to take a reality check. The Nasdaq Composite dropped 1.5%, marking its first negative month since March. Ouch. But here’s the thing—it could’ve been way worse if not for a killer final week that saved everyone from total disaster.
The culprit? Investors finally started asking the uncomfortable question: “Are these valuations actually insane?” Spoiler alert: they kind of were. AI stocks like Nvidia, Palantir, AMD, and Arm Holdings got absolutely hammered. Arm fell 20%, AMD tanked 18%, Palantir dropped 15%, and Nvidia—the darling of the AI boom—plummeted 14%. When the hottest stocks in the market are all bleeding red, you know something’s shifted.
But here’s where it gets interesting. The Nasdaq’s Thanksgiving week surge of 4.9% basically saved the month. That final push lifted the other major indexes into positive territory too, which is kind of wild when you think about it. One good week turned the whole narrative around.
The S&P 500 barely squeaked out a gain—just 0.1% for November—but that 3.7% final week was clutch. Meanwhile, the Dow Jones rose 0.3%, and the Russell 2000 small-cap index gained 0.8%. Not exactly fireworks, but not a bloodbath either.
The real winners? Pharma stocks absolutely crushed it. Biogen led the Nasdaq with a 23.1% jump. On the S&P 500, Albemarle (the lithium play) returned a ridiculous 32.9%, while Eli Lilly added 32.2%. The Dow saw Merck pop 21% and Amgen rise 18%. Basically, if you were in pharma or chemicals, November was your month.
What’s the takeaway here? The market’s finally getting real about valuations. Those AI stocks that were printing money all year? They needed a haircut. And while that’s painful for growth investors, it’s also healthy. Markets can’t just go up forever on hype alone—eventually, earnings and fundamentals have to matter.
Looking ahead, the Nasdaq is still up 20.3% year-to-date, the S&P 500 is up 15.9%, and the Dow is up 11.4%. The Russell 2000 is up 11.1%. So even with November’s correction, we’re still in solid territory for the year. The question now is whether this is just a speed bump or the start of a bigger pullback.
The smart move? Don’t panic. Market corrections happen. They’re actually healthy. But do pay attention to valuations going forward. The days of buying anything with “AI” in the name and expecting 50% returns might be over. Welcome to the part of the cycle where you actually have to think about what you’re buying.
